Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and89Zr-trastuzumab PET

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 936-943

  Janjigian, Yelena Y ^a   Viola Villegas, Nerissa ^a   Holland, Jason P ^a   Divilov, Vadim ^a   Carlin, Sean D ^a   Gomes DaGama, Erica M ^a   Chiosis, Gabriela ^a   Carbonetti, Gregory ^a   De Stanchina, Elisa ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

18f FDG; 89Zr trastuzumab; Afatinib; Gastric cancer; HER2

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOWN REGULATION; DRUG MONITORING; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE NEU; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

18F-FDG; 89ZR-TRASTUZUMAB; AFATINIB; GASTRIC CANCER; HER2;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOCHEMISTRY; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84878663006     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.110239     Document Type: Article

References (37)

1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697.
2. Tafe LJ, Janjigian YY, Zaidinski M, et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med. 2011; 135: 1460-1465.
3. Hofmann M, Stoss O, Shi D, et al. Assessment of a Her2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805. (Pubitemid 351724903)
4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137. (Pubitemid 33674041)
6. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13: 539-548.
7. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012; 29: 2481-2491.
8. Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012; 77: 2-8.
9. Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012; 134: 1149-1159.
10. De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012; 76: 123-127.
11. Hickish T, Wheatley D, Lin N, et al. Use of BIBW 2992, a novel irreversible EGFR/HER1 and her2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res. 2009; 69( 24 suppl): 5060.
12. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. (Pubitemid 47308659)
13. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065. (Pubitemid 32565444)
14. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. (Pubitemid 46646244)
15. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30:288-295. (Pubitemid 36686849)
16. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706. (Pubitemid 38702826)
17. 64Cu- DOTA-trastuzumab. Eur J Nucl Med Mol Imaging. 2009; 36: 1510-1519.
18. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006;47:793-796. (Pubitemid 46768442)
19. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009; 36: 729-739.
20. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2 expression in mice using Zr-DFO-trastuzumab. PLoS ONE. 2010; 5: e8859.
21. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51: 1293-1300.
22. Anderson CJ, Connett JM, Schwarz SW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med. 1992; 33: 1685-1691.
23. Anderson CJ, Schwarz SW, Connett JM, et al. Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab′)2. J Nucl Med. 1995; 36: 850-858.
24. Lindmo T, Bunn PA Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol. 1986;121:678-691. (Pubitemid 16057942)
25. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS ONE. 2010; 5: e10857.
26. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009; 119: 3000-3010.
27. 89Zr-albumin as a model system. J Nucl Med. 2011; 52: 625-633.
28. Sawyers CL. The cancer biomarker problem. Nature. 2008; 452: 548-552.
29. de Vries EGE, Munnink THO, van Vugt MATM, Nagengast WB. Toward molecular imaging-driven drug development in oncology. Cancer Discov. 2011; 1: 25-28.
30. Leyland-Jones B, Colomer R, Trudeau ME, et al. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol. 2010; 28: 960-966.
31. Oude Munnink TH, Dijkers EC, Netters SJ, et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol. 2010; 28: e355-356.
32. Nagengast WB, Lub-de Hooge MN, Oosting SF, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011; 71: 143-153.
33. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87: 586-592.
34. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26: 3204-3212.
35. McArthur GA, Puzanov I, Amaravadi R, et al. Marked, homogeneous, and early [18f]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012; 30: 1628-1634.
36. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004; 45: 17-21.
37. 18F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011; 52: 1684-1689.